Primary Site >> Colorectal Cancer

Gene >> MED12

Journal: Int J Cancer. 2012 Sep 15;131(6):E1044-7.
Title: Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors.
Author: Je, Eun Mi|Kim, Mee Ran|Min, Ki Ouk|Yoo, Nam Jin|Lee, Sug Hyung
PMID: 22532225
Journal: Br J Cancer. 2012 Nov 6;107(10):1761-5.
Title: Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer.
Author: Kampjarvi, K|Makinen, N|Kilpivaara, O|Arola, J|Heinonen, H-R|Bohm, J|Abdel-Wahab, O|Lehtonen, H J|Pelttari, L M|Mehine, M|Schrewe, H|Nevanlinna, H|Levine, R L|Hokland, P|Bohling, T|Mecklin, J-P|Butzow, R|Aaltonen, L A|Vahteristo, P
PMID: 23132392
Journal: Cell. 2012 Nov 21;151(5):937-50.
Title: MED12 controls the response to multiple cancer drugs through regulation of TGF-beta receptor signaling.
Author: Huang, Sidong|Holzel, Michael|Knijnenburg, Theo|Schlicker, Andreas|Roepman, Paul|McDermott, Ultan|Garnett, Mathew|Grernrum, Wipawadee|Sun, Chong|Prahallad, Anirudh|Groenendijk, Floris H|Mittempergher, Lorenza|Nijkamp, Wouter|Neefjes, Jacques|Salazar, Ramo
PMID: 23178117
Journal: Clin Cancer Res. 2014 Jan 1;20(1):265-72.
Title: Modeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patients.
Author: Guinney, Justin|Ferte, Charles|Dry, Jonathan|McEwen, Robert|Manceau, Gilles|Kao, K J|Chang, Kai-Ming|Bendtsen, Claus|Hudson, Kevin|Huang, Erich|Dougherty, Brian|Ducreux, Michel|Soria, Jean-Charles|Friend, Stephen|Derry, Jonathan|Laurent-Puig, Pierre
PMID: 24170544
Journal: Hum Mutat. 2014 Sep;35(9):1136-41.
Title: Mutations in Exon 1 highlight the role of MED12 in uterine leiomyomas.
Author: Kampjarvi, Kati|Park, Min Ju|Mehine, Miika|Kim, Nam Hee|Clark, Alison D|Butzow, Ralf|Bohling, Tom|Bohm, Jan|Mecklin, Jukka-Pekka|Jarvinen, Heikki|Tomlinson, Ian P M|van der Spuy, Zephne M|Sjoberg, Jari|Boyer, Thomas G|Vahteristo, Pia
PMID: 24980722
Journal: Acta Biochim Biophys Sin (Shanghai). 2016 Jan;48(1):27-38.
Title: RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.
Author: Fang, Bingliang
PMID: 26350096
Journal: Gut. 2018 Apr;67(4):663-671.
Title: MED12 is recurrently mutated in Middle Eastern colorectal cancer.
Author: Siraj, Abdul K|Masoodi, Tariq|Bu, Rong|Pratheeshkumar, Poyil|Al-Sanea, Nasser|Ashari, Luai H|Abduljabbar, Alaa|Alhomoud, Samar|Al-Dayel, Fouad|Alkuraya, Fowzan S|Al-Kuraya, Khawla S
PMID: 28183795
Journal: J Biol Chem. 2018 Mar 30;293(13):4870-4882.
Title: Oncogenic exon 2 mutations in Mediator subunit MED12 disrupt allosteric activation of cyclin C-CDK8/19.
Author: Park, Min Ju|Shen, Hailian|Spaeth, Jason M|Tolvanen, Jaana H|Failor, Courtney|Knudtson, Jennifer F|McLaughlin, Jessica|Halder, Sunil K|Yang, Qiwei|Bulun, Serdar E|Al-Hendy, Ayman|Schenken, Robert S|Aaltonen, Lauri A|Boyer, Thomas G
PMID: 29440396
Journal: Mol Cell Biol. 2018 May 15;38(11). pii: MCB.00573-17.
Title: Depletion of Mediator Kinase Module Subunits Represses Superenhancer-Associated Genes in Colon Cancer Cells.
Author: Kuuluvainen, Emilia|Domenech-Moreno, Eva|Niemela, Elina H|Makela, Tomi P
PMID: 29507187
Journal: Int J Mol Med. 2018 Aug;42(2):713-725.
Title: Multilayered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/betacatenin signaling activation (Review).
Author: Katoh, Masaru
PMID: 29786110